Partner
5AM Ventures
Jamil M. Beg joined 5AM Ventures in 2017 as a principal and was promoted to Partner in 2020. Since joining 5AM, Mr. Beg has been involved with investments in Akouos (NASDAQ: AKUS), Aprea (NASDAQ: APRE), Kinaset, Pear Therapeutics (NASDAQ: PEAR), RallyBio (NASDAQ: RLYB), and 5AM’s 4:59 Initiative stepping into operating roles.
Prior to 5AM, Mr. Beg was at Sage Therapeutics (NASDAQ: SAGE) where he contributed to building the company through business development, corporate strategy, medical affairs, health economics & outcomes research and commercialization roles.
Previously, Mr. Beg was an investment professional at Quaker Partners and contributed to investments in the firm’s portfolio companies including EKR Therapeutics (acquired by Cornerstone Therapeutics), Transave Inhalation Therapeutics (acquired by Insmed), NuPathe (NASDAQ: PATH, acquired by Teva) and Cempra (NASDAQ: CEMP).
Mr. Beg started his career at Cambridge Pharma Consultancy (acquired by IMS Health) with a focus on pricing, market access and health economics outcomes research strategies for the biopharma industry.
Mr. Beg earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.